Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma

Cancer Investigation

Volumn 21, Issue 2, 2003, Pages 167-176

  Skubitz, Keith M ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Cancer; Chemotherapy; Liposome; Sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; LIPOSOME; MACROGOL; METHOXYPOLY(ETHYLENE GLYCOL); UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ALVEOLAR SOFT PART SARCOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CARDIOTOXICITY; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; EVALUATION; EWING SARCOMA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETICULOENDOTHELIAL SYSTEM; SARCOMA; SKIN TOXICITY; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BONE NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; FATIGUE; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NAUSEA; OSTEOSARCOMA; SARCOMA; SKIN DISEASES; STROKE VOLUME;

EID: 0037740979     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120016412     Document Type: Conference Paper

References (41)

1. Gabizon, A.A.; Barenholz, Y.; Bialer, M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 1993, 10 (5), 703-708.
2. Gabizon, A.; Catane, R.; Uziely, B.; et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res. 1994, 54 (4), 987-992.
3. Northfelt, D.W.; Martin, F.J.; Working, P.; et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 1996, 36 (1), 55-63.
4. Skubitz, K.M.; Hamdan, H.; Thompson, R.C. A phase I study of ambulatory continuous infusion chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (ciCAD) for soft tissue sarcomas. J. Infus. Chemother. 1992, 2, 97-105.
5. Zalupski, M.; Metch, B.; Balcerzak, S.; et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl Cancer Inst. 1991, 83 (13), 926-932.
6. Huang, S.K.; Mayhew, E.; Gilani, S.; Lasic, D.D.; Martin, F.J.; Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992, 52 (24), 6774-6781.
7. Vaage, J.; Barbera, Guillem, E.; Abra, R.; Huang, A.; Working, P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994, 73 (5), 1478-1484.
8. Northfelt, D.W.; Dezube, B.J.; Thommes, J.A.; et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997, 15 (2), 653-659.
9. Madhavan, S.; Northfelt, D.W. Lack of vesicant injury following extravasation of liposomal doxorubicin [letter]. J. Natl. Cancer Inst. 1995, 87 (20), 1556-1557.
10. Northfelt, D.W. Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-related Kaposi's sarcoma (AIDS-KS) lesions than to normal skin. Proc. Am. Soc. Clin. Oncol. 1994, 13, 51 (abstract).
11. Symon, Z.; Peyser, A.; Tzemach, D.; et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999, 86 (1), 72-78.
12. Uziely, B.; Jeffers, S.; Isacson, R.; et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13 (7), 1777-1785.
13. Skubitz, K.M.; Hamdan, H.; Thompson, R.C., Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993, 72 (10), 2963-2969.
14. Antman, K.; Crowley, J.; Balcerzak, S.P.; et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993, 11 (7), 1276-1285.
15. Antman, K.; Crowley, J.; Balcerzak, S.P.; et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998, 82 (7), 1288-1295.
16. Legha, S.S.; Benjamin, R.S.; Mackay, B.; et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982, 96 (2), 133-139.
17. Lokich, J.; Bothe, A.; Zipoli, T.; et al. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J. Clin. Oncol. 1983, 1 (1), 24-28.
18. O'Bryan, R.M.; Baker, L.H.; Gottlieb, J.E., et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977, 39 (5), 1940-1948.
19. Borden, E.C.; Amato, D.A.; Rosenbaum, C.; et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin. Oncol. 1987, 5 (6), 840-850.
20. O'Bryan, R.M.; Luce, J.K.; Talley, R.W.; Gottlieb, J.A.; Baker, L.H.; Bonadonna, G. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973, 32 (1), 1-8.
21. Gottlieb, J.A.; Benjamin, R.S.; Baker, L.H.; et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat. Rep. 1976, 60 (2), 199-203.
22. Bielack, S.S.; Erttmann, R.; Wrinkler, K.; Landbeck, G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur. J. Cancer Clin. Oncol. 1989, 25 (5), 873-882.
23. Blair, S.C.; Zalupski, M.M.; Baker, L.H. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am. J. Clin. Oncol. 1994, 17 (6), 480-484.
24. Kane, M.J. Chemotherapy of advanced soft tissue and osteosarcomas. Semin. Oncol. 1989, 16 (4), 297-304.
25. Samuels, B.L.; Vogelzang, N.J.; Ruane, M.; Simon, M.A. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat. Rep. 1987, 71 (10), 971-972.
26. Schoenfeld, D.A.; Rosenbaum, C.; Horton, J.; Wolter, J.M.; Falkson, G.; DeConti, R.C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982, 50 (12), 2757-2762.
27. Patel, S.R.; Vadhan-Raj, S.; Burgess, M.A.; et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am. J. Clin. Oncol. 1998, 21 (3), 317-321.
28. Le Cesne, A.; Judson, I.; Crowther, D.; et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 2000, 18 (14), 2676-2684.
29. Leyvraz, S.; Bacchi, M.; Cerny, T.; et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK) [see comments]. Ann. Oncol. 1998, 9 (8), 877-884.
30. Santoro, A.; Tursz, T.; Mouridsen, H.; et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group [see comments]. J. Clin. Oncol. 1995, 13 (7), 1537-1545.
31. Dirix, L.Y.; Van Oosterom, A.T. The role of ifosfamide in the treatment of sarcomas. Semin. Oncol. 1989, 116 (1 Suppl. 3), 39-45.
32. Bramwell, V.H.; Mouridsen, H.T.; Santoro, A.; et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 1987, 23 (3), 311-321.
33. Bramwell, V.; Quirt, I.; Warr, D.; et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group - National Cancer Institute of Canada Clinical Trials Group. J. Natl. Cancer Inst. 1989, 81 (19), 1496-1499.
34. Loehrer, P.J., Sr.; Sledge, G.W., Jr.; Nicaise, C.; et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J. Clin. Oncol. 1989, 7 (11), 1655-1659.
35. Mansi, J.L.; Fisher, C.; Wiltshaw, E.; MacMillan, S.; King, M.; Stuart-Harris, R. A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur. J. Cancer Clin. Oncol. 1988, 24 (9), 1439-1443.
36. Yap, B.S.; Baker, L.H.; Sinkovics, J.G.; et al. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat. Rep. 1980, 64 (1), 93-98.
37. Judson, I.; Radford, J.A.; Harris, M.; et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001, 37 (7), 870-877.
38. Toma, S.; Tucci, A.; Villani, G.; Carteni, G.; Spadini, N.; Palumbo, R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res. 2000, 20 (1B), 485-491.
39. Garcia, A.A.; Kempf, R.A.; Rogers, M.; Muggia, F.M. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann. Oncol. 1998, 9 (10), 1131-1133.
40. Chidiac, T.; Budd, G.T.; Pelley, R.; et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas [In Process Citation]. Invest. New Drugs 2000, 18 (3), 253-259.
41. Skubitz, K.M.; Skubitz, A.P. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998, 9 (1), 45.